Navigation Links
Increased Heart Attack Risk From Celebrex,Vioxx

CELEBREX (celecoxib capsules) is used for relief of the pain and inflammation of osteoarthritis and adult rheumatoid arthritis. By effectively reducing the pain, inflammation and stiffness of arthritis, celebrex can help you through the day with activities like standing, walking or climbing stairs, and through the night while sitting or lying in bed.

Since their introduction in 1999, the drugs, which are known technically as COX-2 inhibitors, have been among // America's best-selling prescription pharmaceuticals. One of them, Celecoxib, sold as Celebrex, was the sixth leading prescription drug used by 14 million people last year. The other COX-2 inhibitor is Rofecoxib, sold as Vioxx.

The drugs are popular because they provide the same pain- killing effects as aspirin and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) such as ibuprofen, but with less chance of causing ulcers and intestinal bleeding.

Aspirin inhibits two closely related cyclooxygenase enzymes, COX-1 and COX-2. These new drugs specifically inhibit only the COX-2 (which is involved in pain and inflammation) while not affecting the first (which is involved in protecting lining of the stomach).

Celebrex, was recently approved by the Food and Drug Administration, FDA. The popular pain-killers Celebrex and Vioxx may slightly increase a person's risk of having a heart attack, according to an analysis of clinical studies of these 'super aspirin' drugs.


'"/>




Page: 1

Related medicine news :

1. Use of Cellular Phones associated with Increased risk of Brain Tumors
2. Allergy Risk Increased by Kerosene Use
3. Fewer teeth & Increased Ischemic Stroke risk
4. Young Smokers at Increased Risk Of Developing a Heart Attack
5. Women With Diabetes At Increased Risk Of Developing Cognitive Impairment
6. Asbestos Exposure Associated With An Increased Risk For Autoimmune Disease
7. Schizophrenics On Medication At An Increased Risk For Developing Diabetes
8. Diabetics Found To Be At An Increased Risk Of Developing Cancer
9. Increased Risk For Venous Thrombosis In Cancer Patients
10. Increased risk of common infections in patients suffering from diabetes
11. Infertility Associated With Increased Cancer Risk
Post Your Comments:
(Date:5/22/2008)...Invasive P3(TM) (Pioneer Peek-on-Peek) ...ERGEN, Netherlands, May 22 /PRNewswire/ -- Pioneer...nnounced the BacJac(TM),Interspinous Decompression...ring the International SpineWeek meeting in Geneva...relieve pain in patients with,Neurogenic Intermitt...
(Date:5/22/2008)...Newswire/ -- Whether your summer travel,plans incl... an older adult,there are things you should do bef...ng to Timothy Schwab, M.D., chief medical officer ...ply whether you,re planning to go,out of the count... travel plans with your doctor. If you are (or rec...
(Date:5/22/2008)...May 22, 2008) For patients undergoing kidney tran...g sirolimus may lead to an increased risk of diabe...erican Society of Nephrology (JASN). , "We demon... diabetes after transplantation in a large group o...s," comments Dr. John S. Gill of University of Bri...
(Date:5/22/2008)...-USNewswire/ -- Generation Rescue, a,non-profit or... Autism,ADHD and chronic illness, today announced...ajor steps:, 1. Jenny McCarthy, Deirdre Imus and ... Ms. McCarthy is a best-selling author, actress, a...m autism. Her latest book, Louder than Words,prof...
Breaking Medicine News(10 mins):Health News:Pioneer(R) Surgical Technology Introduces the BacJac(TM) Interspinous Decompression System to the European Spine Market 2Health News:SCAN Health Plan Offers Seniors Ten Tips for Safe and Healthy Travel 2Health News:Anti-rejection drug may increase risk of diabetes after kidney transplant 2Health News:Generation Rescue to Target Treatment-Based Research for Autism and ADHD - Jenny McCarthy, Deirdre Imus, and Katie Wright Join Board 2Health News:Generation Rescue to Target Treatment-Based Research for Autism and ADHD - Jenny McCarthy, Deirdre Imus, and Katie Wright Join Board 3
...ernment is facing accusation from the Victorian Op...ces in the state. // Reports are rife that almost... a month of being discharged from the hospital, ne...ey confirms that the auditor-general had fore-warn...
...ublished in the March 15, 2006 issue of CANCER, a ...ty, says that the risk of a //new cancer occurring...cer increases to a fair degree in women diagnosed .... The study also says that the risk of developing ...
...roposed by the Jharkhand government to donate near...t the potential of Ayurveda.// The yoga guru has a...ure and marketing of Ayurvedic medicine preparatio... medicinal plants. The government is likely to si...
...ia has been long considered a wonderland for smoke...bbies or restaurants without any inhibition. // Sa...t is seriously thinking about imposing a smoking b...In Malaysia and Thailand, smoking bans already exi...
Other Medicine News:Health News:Smoking Ban To Be Soon Implemented In South East Asian Bars 2
(Date:5/21/2008)...1 /- Pressure,BioSciences, ... scientists,from the New York University (NYU) Sch... the Harvard School of Public Health made presenta... patented pressure cycling,technology (PCT) at thr....,There were three oral presentations and four pos...
(Date:5/21/2008)...an Urological Association Annual Meeting -, SEATT.../ -- Researchers,from Dendreon Corporation (Nasdaq...rating the potential of D-3263, Dendreon,s orally ...(a transmembrane cation channel protein also,known... (BPH)., The abstract (#2041), "Preclinical Valid...
(Date:5/20/2008)...ay 21 /- Today at the,World...e entitled "New,Perspectives in Atrial Fibrillatio...linical Cardiology, St George,s University of Lond...ced ATHENA clinical trial,results, as the way forw...n, the most common form of cardiac arrhythmia., T...
(Date:5/20/2008)...ed today at Digestive Disease Week -, CAMBRIDGE, ...--,Ironwood Pharmaceuticals, Inc. (formerly Microb...X ) today announced the presentation of data,from ...olled study,assessing the safety and efficacy of l...CC). Analysis of these data indicate that linaclot...
Breaking Medicine Technology:Seven Presentations by Two Independent Research Groups Highlight Advantages of Pressure Cycling Technology (PCT) at Scientific Symposia in Philadelphia, Boston, and New York City 2Seven Presentations by Two Independent Research Groups Highlight Advantages of Pressure Cycling Technology (PCT) at Scientific Symposia in Philadelphia, Boston, and New York City 3Seven Presentations by Two Independent Research Groups Highlight Advantages of Pressure Cycling Technology (PCT) at Scientific Symposia in Philadelphia, Boston, and New York City 4Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia 2Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia 3Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia 4ATHENA Clinical Results for Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress 2ATHENA Clinical Results for Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress 3ATHENA Clinical Results for Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress 4ATHENA Clinical Results for Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress 5ATHENA Clinical Results for Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress 6Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results 2Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results 3Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results 4Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results 5Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results 6Nucletron Announces Oncentra 28R 29 Brachy Treatment Planning Solution for Multimodality Environment 4906 1Nucletron Announces Oncentra 28R 29 Brachy Treatment Planning Solution for Multimodality Environment 4906 2Terumo Heart Summarizes Results of DuraHeart 28TM 29 LVAS Implants 1913 1Terumo Heart Summarizes Results of DuraHeart 28TM 29 LVAS Implants 1913 2Will you be misdiagnosed 3F how diagnostic errors happen 17851 1Will you be misdiagnosed 3F how diagnostic errors happen 17851 2Will you be misdiagnosed 3F how diagnostic errors happen 17851 3American Chemical Societys Weekly PressPac April 23 2008 3076 1American Chemical Societys Weekly PressPac April 23 2008 3076 2American Chemical Societys Weekly PressPac April 23 2008 3076 3American Chemical Societys Weekly PressPac April 23 2008 3076 4American Chemical Societys Weekly PressPac April 23 2008 3076 5American Chemical Societys Weekly PressPac April 23 2008 3076 6American Chemical Societys Weekly PressPac April 23 2008 3076 7American Chemical Societys Weekly PressPac April 23 2008 3076 8
...r 7, 2007 - Gemin X,announced today that a report ...od demonstrated that its lead compound, GX15-070,(...inst,patient-derived multiple myeloma tumor cells ...ts when used as a combination therapy.,GX15-070 is... all,relevant members of the Bcl-2 protein family,...
...erican College of,Cardiology,s Scientific Session ...irstCall/ -- CV,Therapeutics, Inc. announced today...N TIMI-36 study of ranolazine shows there was no,a...n ranolazine.,The study did not meet the primary e...,s special protocol assessment,agreement with the ...
Other Medicine Technology:Gemin X Announces Publication of Preclinical Data of GX15-070 in,Multiple Myeloma in Blood 2CV Therapeutics Announces Topline MERLIN TIMI-36 Results 2CV Therapeutics Announces Topline MERLIN TIMI-36 Results 3
...nfiguration offers all the performance of a major ...y for use in Outpatient Settings, Minor Procedure ...two single lights either side of the OR table is b... combining Flat Screen LCD Monitors with the light...
A Western Blot Immunassay for the detection of antibodies to primarily anti-myelin associated glycoproteins (anti-MAG) and other glycolipid autoantibodies in human serum.
Triturus® is an open and completely automated ELISA immunoassay analyzer which can perform a variety of different tests on a series of samples and process several batches simultaneously.
...ors in Anesthesia and Respiratory Products, ,West...lity medical devices for Anesthesia and Respirator...facture products that enhance the clinician's abil...lose attention to the bottom line. , ,Our web sit...
Medicine Products: